Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis.

ABSTRACT: Given the rapidly evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL), we performed a contemporary analysis of survival outcomes in patients aged ≥18 years with DLBCL at the population level using linked administrative data sets in Ontario, Canada (ICES). Among 8675 patients (median age, 67 years; 44% female) treated with frontline rituximab-based therapy, 1675 (19%) were treated with second-line therapy (2L). The 2-year and 5-year overall survival (OS) from 2L were 33% and 26%, respectively. Univariate analysis demonstrated that curative-intent therapy (autologous stem cell transplantation [ASCT]) (58% of patients) was associated with better OS than palliative radiotherapy (hazard ratio [HR], 0.56; P < .0001). Patients aged ≥60 years showed inferior OS than those

SUBMITTER: Gong IY 

PROVIDER: S-EPMC12318267 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature